

Chi-Yung Shang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/793786/publications.pdf>

Version: 2024-02-01

39
papers

2,026
citations

279798

23
h-index

302126

39
g-index

39
all docs

39
docs citations

39
times ranked

2323
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale "parent form. <i>International Journal of Methods in Psychiatric Research</i> , 2008, 17, 35-44.	2.1	262
2	Association between Morningness-Eveningness and Behavioral/Emotional Problems among Adolescents. <i>Journal of Biological Rhythms</i> , 2007, 22, 268-274.	2.6	234
3	Executive functions as endophenotypes in ADHD: evidence from the Cambridge Neuropsychological Test Battery (CANTAB). <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 838-849.	5.2	172
4	Psychiatric Comorbidity Among Children and Adolescents With and Without Persistent Attention-Deficit Hyperactivity Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 135-143.	2.3	129
5	Association between childhood sleep problems and perinatal factors, parental mental distress and behavioral problems. <i>Journal of Sleep Research</i> , 2006, 15, 63-73.	3.2	123
6	Associations Between Chronotypes, Psychopathology, and Personality Among Incoming College Students. <i>Chronobiology International</i> , 2012, 29, 491-501.	2.0	106
7	Association between symptoms and subtypes of attention-deficit hyperactivity disorder and sleep problems/disorders. <i>Journal of Sleep Research</i> , 2010, 19, 535-545.	3.2	103
8	Psychometric properties of the Chinese version of Strength and Difficulties Questionnaire. <i>Comprehensive Psychiatry</i> , 2013, 54, 720-730.	3.1	98
9	Psychometric Properties of the Chinese Version of the Swanson, Nolan, and Pelham, Version IV Scale-Teacher Form. <i>Journal of Pediatric Psychology</i> , 2009, 34, 850-861.	2.1	79
10	Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 243.	2.1	78
11	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 447-460.	1.3	59
12	Increased gene expression of FOXP1 in patients with autism spectrum disorders. <i>Molecular Autism</i> , 2013, 4, 23.	4.9	53
13	A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1959-1973.	2.1	53
14	Whole Brain White Matter Tract Deviation and Idiosyncrasy From Normative Development in Autism and ADHD and Unaffected Siblings Link With Dimensions of Psychopathology and Cognition. <i>American Journal of Psychiatry</i> , 2021, 178, 730-743.	7.2	36
15	Executive Function in Adolescence Among Children With Attention-Deficit/Hyperactivity Disorder in Taiwan. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2009, 30, 525-534.	1.1	35
16	The interactions between religion, religiosity, religious delusion/hallucination, and treatment-seeking behavior among schizophrenic patients in Taiwan. <i>Psychiatry Research</i> , 2011, 187, 347-353.	3.3	35
17	Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study. <i>European Neuropsychopharmacology</i> , 2015, 25, 2300-2310.	0.7	33
18	Improving Visual Memory, Attention, and School Function with Atomoxetine in Boys with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 353-363.	1.3	30

#	ARTICLE	IF	CITATIONS
19	Association between the dopamine transporter gene and the inattentive subtype of attention deficit hyperactivity disorder in Taiwan. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 421-428.	4.8	29
20	Emotional/Behavioral Problems and Functional Impairment in Clinic- and Community-Based Children with Attention-Deficit/Hyperactivity Disorder in Taiwan. <i>Journal of Abnormal Child Psychology</i> , 2010, 38, 521-532.	3.5	28
21	Impaired sustained attention, focused attention, and vigilance in youths with autistic disorder and Asperger's disorder. <i>Research in Autism Spectrum Disorders</i> , 2014, 8, 881-889.	1.5	26
22	An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 566-573.	1.3	26
23	Psychiatric Comorbidities in Adolescents with Attention- Deficit Hyperactivity Disorder and Their Siblings. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 281-292.	1.9	23
24	Association between the DAT1 gene and spatial working memory in attention deficit hyperactivity disorder. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 9-21.	2.1	23
25	Differential brain activations in adult attention-deficit/ hyperactivity disorder subtypes: a counting Stroop functional MRI study. <i>Brain Imaging and Behavior</i> , 2018, 12, 882-890.	2.1	20
26	Demographic and perinatal factors for behavioral problems among children aged 4-9 in Taiwan. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 569-576.	1.8	19
27	Visual processing as a potential endophenotype in youths with attention-deficit/hyperactivity disorder: A sibling study design using the counting Stroop functional MRI. <i>Human Brain Mapping</i> , 2018, 39, 3827-3835.	3.6	16
28	The norepinephrine transporter gene modulates intrinsic brain activity, visual memory, and visual attention in children with attention-deficit/hyperactivity disorder. <i>Molecular Psychiatry</i> , 2019, 26, 4026-4035.	7.9	15
29	Associations of symptoms and subtypes of attention-deficit hyperactivity disorder with visuospatial planning ability in youth. <i>Research in Developmental Disabilities</i> , 2013, 34, 2986-2995.	2.2	12
30	Maternal and Family Processes in Different Subgroups of Youth with Autism Spectrum Disorder. <i>Journal of Abnormal Child Psychology</i> , 2019, 47, 177-194.	3.5	11
31	Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 148-158.	1.3	11
32	Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 187-196.	1.3	11
33	A haplotype of the norepinephrine transporter gene (SLC6A2) is associated with visual memory in attention-deficit/hyperactivity disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 58, 89-96.	4.8	8
34	Effects of the dopamine transporter gene on striatal functional connectivity in youths with attention-deficit/hyperactivity disorder. <i>Psychological Medicine</i> , 2021, 51, 835-845.	4.5	8
35	Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 9-19.	1.3	7
36	A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 164-178.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Neural substrates underpinning intra-individual variability in children with ADHD: A voxel-based morphometry study. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 546-556.	1.7	4
38	Social adjustment and family function after drug switch from IR -methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2783-2791.	2.2	3
39	Serotonin-Norepinephrine Reuptake Inhibitor-associated Mixed Episode in an Adolescent With Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 525-526.	1.4	2